Hematopoietic stem cell transplantation in its 60s: a platform for cellular therapies
Over the last 60 years, more than a million patients received hematopoietic cell
transplantation. Having incorporated multiple changes in clinical practices, it remains a …
transplantation. Having incorporated multiple changes in clinical practices, it remains a …
[HTML][HTML] Clinical practice recommendation on hematopoietic stem cell transplantation for acute myeloid leukemia patients with FLT3-internal tandem duplication: a …
The FMS-like tyrosine kinase 3 (FLT3) gene is mutated in 25-30% of patients with acute
myeloid leukemia (AML). Because of the poor prognosis associated with FLT3-internal …
myeloid leukemia (AML). Because of the poor prognosis associated with FLT3-internal …
Immune effector cell–associated hematotoxicity: EHA/EBMT consensus grading and best practice recommendations
Hematological toxicity is the most common adverse event after chimeric antigen receptor
(CAR) T-cell therapy. Cytopenias can be profound and long-lasting and can predispose for …
(CAR) T-cell therapy. Cytopenias can be profound and long-lasting and can predispose for …
[HTML][HTML] Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort …
Background Mortality of patients with coronavirus disease 2019 (COVID-19), acute
respiratory distress syndrome (ARDS), and systemic inflammation is high. In areas of …
respiratory distress syndrome (ARDS), and systemic inflammation is high. In areas of …
[HTML][HTML] Microvascular COVID-19 lung vessels obstructive thromboinflammatory syndrome (MicroCLOTS): an atypical acute respiratory distress syndrome working …
F Ciceri, L Beretta, AM Scandroglio, S Colombo… - Critical care and …, 2020 - Elsevier
We suggest the use of MicroCLOTS (microvascular COVID-19 lung vessels obstructive
thromboinflammatory syndrome) as a new name for severe pulmonary coronavirus disease …
thromboinflammatory syndrome) as a new name for severe pulmonary coronavirus disease …
Efficacy and safety of tocilizumab in severe COVID-19 patients: a single-centre retrospective cohort study
Background Tocilizumab (TCZ), a humanized monoclonal antibody targeting the interleukin-
6 (IL-6) receptor, has been proposed for the treatment of COVID-19 patients; however …
6 (IL-6) receptor, has been proposed for the treatment of COVID-19 patients; however …
Effect of graft source on unrelated donor haemopoietic stem-cell transplantation in adults with acute leukaemia: a retrospective analysis
Background Umbilical-cord blood (UCB) is increasingly considered as an alternative to
peripheral blood progenitor cells (PBPCs) or bone marrow, especially when an HLA …
peripheral blood progenitor cells (PBPCs) or bone marrow, especially when an HLA …
Early predictors of clinical outcomes of COVID-19 outbreak in Milan, Italy
F Ciceri, A Castagna, P Rovere-Querini, F De Cobelli… - Clinical …, 2020 - Elsevier
Background National health-system hospitals of Lombardy faced a heavy burden of
admissions for acute respiratory distress syndromes associated with coronavirus disease …
admissions for acute respiratory distress syndromes associated with coronavirus disease …
The first case of COVID-19 treated with the complement C3 inhibitor AMY-101
S Mastaglio, A Ruggeri, AM Risitano, P Angelillo… - Clinical …, 2020 - Elsevier
Acute respiratory distress syndrome (ARDS) is a devastating clinical manifestation of COVID-
19 pneumonia and is mainly based on an immune-driven pathology. Mounting evidence …
19 pneumonia and is mainly based on an immune-driven pathology. Mounting evidence …
[HTML][HTML] Characteristics, treatment, outcomes and cause of death of invasively ventilated patients with COVID-19 ARDS in Milan, Italy
Objective: Describe characteristics, daily care and outcomes of patients with coronavirus
disease 2019 (COVID-19) acute respiratory distress syndrome (ARDS). Design: Case series …
disease 2019 (COVID-19) acute respiratory distress syndrome (ARDS). Design: Case series …